Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Allantoin→

Allantoin Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
97-59-6
Molecular formula
C4H6N4O3
Molecular weight
158.12 g/mol
Drug class
Topical skin protectant and conditioning agentkeratolytic/wound-care ingredient
Mechanism of action
Provides local skin-protective and conditioning effects. It may support hydration and softening of the stratum corneum and is used in topical products to protect irritated or damaged skin; a single defined systemic molecular target is not established.
Indications / reported uses
  • Topical protection and care of minor skin irritation, dry or rough skin and superficial wounds in authorised skin-protectant or wound-care formulations; exact claims depend on the product and jurisdiction

Sources: US eCFR — Skin protectant drug products, 21 CFR Part 347 · PubChem — Allantoin · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Allantoin Environmental Risk Assessment (ERA) (the Allantoin ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.